Antithrombotic strategies in non-ST elevation acute coronary syndromes: Focus on bivalirudin

Future Cardiology

Volumn 3, Issue 4, 2007, Pages 345-364

  Nikolsky, Eugenia ^a   Stone, Gregg W ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Department of Medicine   (United States)

Author keywords

Acute coronary syndrome; Bivalirudin; Invasive

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; NITRATE; PLACEBO; THROMBIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANAPHYLAXIS; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; EPISTAXIS; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; HEART CATHETERIZATION; HEART REINFARCTION; HEMOPERICARDIUM; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INJECTION SITE BLEEDING; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG HEMORRHAGE; MONOTHERAPY; MORTALITY; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 34447321818     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.3.4.345     Document Type: Review

References (80)

1. National Center for Health Statistics: Detailed Diagnosis and Procedures: National Hospital Discharge Survey 1996, Hyattsville, MD. National Center for health Statistics. Data from Vital and Health Statistics 13 (1998).
2. Antman EM, Cohen M, Bernink PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284, 835-842 (2000).
3. Sabatine MS, McCabe CH, Morrow DA et al.: Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am. Heart J. 143, 966-970 (2002).
4. Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 102, 118-122 (2000).
5. Scirica BM, Cannon CP, McCabe CH et al.: Thrombolysis in Myocardial Ischemia III Registry Investigators. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am. J. Cardiol. 90, 821-826 (2002).
6. Falk E, Shah PK, Fuster V: Pathogenesis of plaque disruption. In: Atherosclerosis and Coronary Artery Disease. Fuster V, Ross R, Topol EJ (Eds). J B Lippincott, Philadelphia, PA, USA 492-511 (1996).
7. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336, 1276-1282 (1997).
8. Yamagishi M, Terashima M, Awano K et al.: Morphology of vulnerable plaque: insights from follow-up of patients examined by intravscular ultrasound before an acute coronary syndrome. J. Am. Coll. Cardiol. 35, 106-111 (2000).
9. Burke AP, Kolodgie FD, Farb A et al.: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103, 934-940 (2001).
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326, 242-250 (1992).
11. Packham MA, Mustard JF: The role of platelets in the development and complications of atherosclerosis. Semin. Hematol. 23, 8-26 (1986).
12. Cannon CP, Weintraub WS, Demopoulos LA et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344, 1879-1887 (2001).
13. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease Investigators: Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354, 708-715 (1999).
14. Fox KA, Poole-Wilson PA, Henderson RA et al.: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial: Randomized Intervention Trial of unstable Angina. Lancet 360, 743-751 (2002).
15. Gibler WB, Cannon CP, Blomkalns AL et al.: American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care); Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group; Society of Chest Pain Centers Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology(Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 111, 2699-2710 (2005).
16. Braunwald E, Antman EM, Beasley JW et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article. Circulation 106, 1893-1900 (2002).
17. de Winter RJ, Windhausen F, Cornel JH et al.: Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N. Engl. J. Med. 353, 1095-1104 (2005).
18. Mehta SR, Cannon CP, Fox KA et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293, 2908-2917 (2005).
19. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT: Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J. Am. Coll. Cardiol. 48, 1319-1325 (2006).
20. Rao SV, O'Grady K, Pieper KS et al.: Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am. J. Cardiol. 96, 1200-1206 (2005).
21. Rao SV, Jollis JG, Harrington RA et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292, 1555-1562 (2004).
22. Yang X, Alexander KP, Chen AY et al.: CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J. Am. Coll. Cardiol. 46, 1490-1495 (2005).
23. Milkovich G, Gibson G: Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am. J. Health Syst. Pharm. 60(14 Suppl. 3), S15-S21 (2003).
24. Bertrand ME, Simoons ML, Fox KA et al.: Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 23, 1809-1840 (2002).
25. Collins R, Baigent C, Sandercock P, Peto R: Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. Br. Med. J. 309(6963), 1215-1217 (1994).
26. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
27. Mehta SR, Yusuf S, Peters RJ et al.: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527-533 (2001).
28. Fox KA, Mehta SR, Peters R et al.: Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110, 1202-1208 (2004).
29. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP: Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J. Thromb. Thrombolysis (2007) (Epub ahead of print).
30. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. Cardiol. 40, 231-237 (2002).
31. Chan AW, Moliterno DJ, Berger PB et al.: TARGET Investigators. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J. Am. Coll. Cardiol. 42, 1188-1195 (2003).
32. Cuisset T, Frere C, Quilici J et al.: Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48, 1339-1345 (2006).
33. Montalescot G, Sideris G, Meuleman C et al.: ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
34. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111, 2099-2106 (2005).
35. Topol EJ, Califf RM, Weisman HF et al.: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 881-886 (1994).
36. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 339, 1861-1863 (1998).
37. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352, 87-92 (1998).
38. The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338, 1498-1505 (1998).
39. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349, 1429-1435 (1997).
40. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 338, 1488-1497 (1998).
41. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 339, 436-443 (1998).
42. Boersma E, Akkerhuis KM, Theroux P et al.: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 100, 2045-2048 (1999).
43. van den Brand M, Laarman GJ, Steg PG et al.: Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur. Heart J. 20, 1572-1578 (1999).
44. Zhao X-Q, Theroux P, Snapinn SM et al.: Intracoronary thrombus and platelet glycoprotrein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 100, 1609-1615 (1999).
45. Boersma E, Harrington RA, Moliterno DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359, 189-198 (2002).
46. McCullough PA, Gibson CM, Dibattiste PM et al.: TACTICS-TIMI-18 Investigators. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J. Interv. Cardiol. 17, 81-86 (2004).
47. The GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357, 1915-1924 (2001).
48. Petitou M, Casu B, Lindahl U: 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 85, 83-89 (2003).
49. Chew DP, Bhatt DL, Lincoff AM et al.: Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103, 961-966 (2001).
50. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ: Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of coronary interventions. Circulation 110, 994-998 (2004).
51. Blazing MA, de Lemos JA, Dyke CK et al.: The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am. Heart J. 142, 211-217 (2001).
52. Ferguson JJ, Califf RM, Antman EM et al.: Enoxaparin vs unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292, 45-54 (2004).
53. Turpie AG, Bauer KA, Eriksson BI et al.: PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359, 1721-1726 (2002).
54. Bauer KA, Eriksson BI, Lassen MR et al.: Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery, N. Engl. J. Med. 345, 1305-1310 (2001).
55. Buller HR, Davidson BL, Decousus H et al.: Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349, 1695-1702 (2003).
56. Buller HR, Davidson BL, Decousus H et al.: Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. 140, 867-873 (2004).
57. Yusuf S, Mehta SR, Chrolavicius S et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; N. Engl. J. Med. 354, 1464-1476 (2006).
58. Yusuf S, Mehta SR, Chrolavicius S et al.: OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295, 1519-1530 (2006).
59. Becker RC: Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting. J. Thromb. Thrombolysis 10(Suppl. 1), 59-68 (2000).
60. Metz BK, White HD, Granger CB et al.: Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J. Am. Coll. Cardiol. 31, 1493-1498 (1998).
61. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94, 911-921 (1996).
62. Effects of recombinant hirudin (lepitudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 353, 429-438 (1999).
63. Mahaffey KW, Lewis BE, Wildermann NM et al.: ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invasive Cardiol. 15, 611-616 (2003).
64. Lincoff AM, Kleiman NS, Kottke-Marchant K et al.: Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am. Heart J. 143, 847-853 (2002).
65. Lincoff AM, Kleiman NS, Kereiakes DJ et al.: REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292, 696-703 (2004).
66. Cheneau E, Canos D, Kuchulakanti PK et al.: Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. Am. J. Cardiol. 94, 789-792 (2004).
67. Greinacher A, Lubenow N, Eichler P: Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108, 2062-2065 (2003).
68. Bittl JA, Strony J, Brinker JA et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N. Engl. J. Med. 333, 764-769 (1995).
69. Bird JA, Chaitman BR, Feit F, Kimball W, Topol EJ: Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. 142, 952-959 (2001).
70. Lincoff AM, Bittl JA, Kleiman NS et. al.: REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am. J. Cardiol. 93, 1092-1096 (2004).
71. Gurm HS, Sarembock IJ, Kereiakes DJ et al.: Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J. Am. Coll. Cardiol. 45, 1932-1938 (2005).
72. Nikolsky E, Stone GW, Mehran R et al.: Impact of age and choice of procedural antithrombotic regimen on ischemic and hemorrhagic outcomes following percutaneous coronary intervention: analysis from the REPLACE-2 trial. Transcatheter Therapeutics, Washington, September 2005. Am. J. Cardiol. 96(Suppl. 7), 312 (2005).
73. Chew DP, Lincoff AM, Gurm H et al.: REPLACE-2 Investigators. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am. J. Cardiol. 95, 581-585 (2005).
74. Rajagopal V, Lincoff AM, Cohen DJ et al.: Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am. Heart J. 152, 149-154 (2006).
75. Cohen DJ, Lincoff AM, Lavelle TA et al.: Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J. Am. Coll. Cardiol. 9, 1792-1800 (2004)
76. Fuchs J, Cannon CP: Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI)-7 trial. Circulation 92, 727-733 (1995).
77. Antman EM, McCabe CH, Braunwald E: Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am. Heart J. 143, 229-234 (2002).
78. Stone GW, Bertrand M, Colombo A et al.: Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am. Heart J. 148, 764-775 (2004).
79. Stone GW, McLaurin BT, Cox DA et al.: For the ACUTTY Investigators. Bivalirudin for Patients with Acute Coronary Syndromes. N. Engl. J. Med. 355, 2203-2216 (2006).
80. Gibson CM, Morrow DA, Murphy SA et al.: For the TIMI Study Group. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial. J. Am. Coll. Cardiol. 47, 2364--2373 (2006).